Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Bagel

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Journal of Drugs in Dermatology : JDD|October 27, 2018
Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled TrialsLawrence J Green, Francisco A Kerdel, Fran E Cook-Bolden, et al.
Journal of the American Academy of Dermatology|March 30, 2024
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b studyKurt Gebauer, Lynda Spelman, Paul S Yamauchi, et al.
Journal of the American Academy of Dermatology|May 12, 2023
Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trialJerry Bagel, Linda Stein Gold, James Del Rosso, et al.
Medical Devices (Auckland, N.Z.)|October 28, 2016
Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experienceKristina Callis Duffin, Michael Bukhalo, Margaret A Bobonich, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 StudiesJeffrey L Sugarman, Jonathan Weiss, Emil A Tanghetti, et al.
Journal of Drugs in Dermatology : JDD|April 3, 2008
Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomesLeon Kircik, Jerry Bagel, Neil Korman, et al.
Dermatology and Therapy|November 17, 2022
Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis RegistryChen Yu, Gang Wang, Russel T Burge, et al.
Archives of Dermatology|December 22, 2010
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trialCraig Leonardi, Richard G Langley, Kim Papp, et al.
The British Journal of Dermatology|June 23, 2026
Dupilumab treatment restores skin nerve fibre density in patients with moderate-to-severe atopic dermatitis: results from DIFFERENSTAD, an open-label exploratory studyKonstantin Agelopoulos, Leigh Nattkemper, Felix Witte, et al.
The Journal of Dermatological Treatment|May 5, 2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasisAndrew Blauvelt, Kenneth B Gordon, Patricia Lee, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Journal of Drugs in Dermatology : JDD|October 27, 2018
Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled TrialsLawrence J Green, Francisco A Kerdel, Fran E Cook-Bolden, et al.
Journal of the American Academy of Dermatology|March 30, 2024
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b studyKurt Gebauer, Lynda Spelman, Paul S Yamauchi, et al.
Journal of the American Academy of Dermatology|May 12, 2023
Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trialJerry Bagel, Linda Stein Gold, James Del Rosso, et al.
Medical Devices (Auckland, N.Z.)|October 28, 2016
Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experienceKristina Callis Duffin, Michael Bukhalo, Margaret A Bobonich, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 StudiesJeffrey L Sugarman, Jonathan Weiss, Emil A Tanghetti, et al.
Journal of Drugs in Dermatology : JDD|April 3, 2008
Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomesLeon Kircik, Jerry Bagel, Neil Korman, et al.
Dermatology and Therapy|November 17, 2022
Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis RegistryChen Yu, Gang Wang, Russel T Burge, et al.
Archives of Dermatology|December 22, 2010
Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trialCraig Leonardi, Richard G Langley, Kim Papp, et al.
The British Journal of Dermatology|June 23, 2026
Dupilumab treatment restores skin nerve fibre density in patients with moderate-to-severe atopic dermatitis: results from DIFFERENSTAD, an open-label exploratory studyKonstantin Agelopoulos, Leigh Nattkemper, Felix Witte, et al.
The Journal of Dermatological Treatment|May 5, 2021
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasisAndrew Blauvelt, Kenneth B Gordon, Patricia Lee, et al.
Pageof 10